Inovio Pharmaceuticals Appoints Dr. Ami Shah Brown As Vice President Regulatory Affairs
August 04 2016 - 8:00AM
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the
appointment of Dr. Ami Shah Brown as Vice President Regulatory
Affairs. Dr. Brown, who joined Inovio in 2011 as Senior Director of
Regulatory Affairs, will be responsible for developing and
implementing Inovio’s regulatory strategies, including leadership
over regulatory submissions, regulatory compliance, advertising and
promotion review, and registrations to support Inovio’s product
pipeline.
Dr. J. Joseph Kim, Inovio’s President & CEO,
said, “Ami has shown technical excellence and leadership in
successfully moving our DNA-based therapy for women’s health,
VGX-3100, through its phase II regulatory process. This is now
leading to the initiation of phase III for this program before the
end of this year. We expect her strategic guidance and counsel to
be invaluable as we advance multiple cancer and infectious disease
products through the clinical and regulatory
process.”
Prior to Inovio, Dr. Brown was Director, Vaccine
Operations, at the Sabin Vaccine Institute in Washington, D.C.,
where she contributed to the early work of the Sabin Vaccine
Institute Product Development Partnership (Sabin PDP), an
internationally recognized PDP for the creation of safe, effective,
low-cost vaccines for tropical infections in developing countries.
She had previous experience at the Johns Hopkins Bloomberg School
of Public Health’s Center for Immunization Research, the Emory
University Department of Medicine, and the Centers for Disease
Control and Prevention (CDC) at the National Center for HIV, STD
and TB prevention. She began her career at the University of
Pennsylvania Department of Pathology and Laboratory Medicine.
She holds a PhD from Johns Hopkins University’s
Bloomberg School of Public Health, a Master of Public Health (MPH)
degree from Emory University’s Rollins School of Public Health, and
a BA in Biology from the University of Pennsylvania.
About Inovio Pharmaceuticals,
Inc.
Inovio is taking immunotherapy to the next level
in the fight against cancer and infectious diseases. We are the
only immunotherapy company that has reported generating T cells in
vivo in high quantity that are fully functional and whose killing
capacity correlates with relevant clinical outcomes with a
favorable safety profile. With an expanding portfolio of immune
therapies, the company is advancing a growing preclinical and
clinical stage product pipeline. Partners and collaborators include
MedImmune, The Wistar Institute, University of Pennsylvania, DARPA,
GeneOne Life Science, Plumbline Life Sciences, Drexel University,
NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S.
Military HIV Research Program, and Laval University. For more
information, visit www.inovio.com.
This press release contains certain
forward-looking statements relating to our business, including our
plans to develop electroporation-based drug and gene delivery
technologies and DNA vaccines, our expectations regarding our
research and development programs and our capital resources. Actual
events or results may differ from the expectations set forth herein
as a result of a number of factors, including uncertainties
inherent in pre-clinical studies, clinical trials and product
development programs (including, but not limited to, the fact that
pre-clinical and clinical results referenced in this release may
not be indicative of results achievable in other trials or for
other indications, that the studies or trials may not be successful
or achieve the results desired, that pre-clinical studies and
clinical trials may not commence or be completed in the time
periods anticipated, that results from one study may not
necessarily be reflected or supported by the results of other
similar studies and that results from an animal study may not be
indicative of results achievable in human studies), the
availability of funding to support continuing research and studies
in an effort to prove safety and efficacy of electroporation
technology as a delivery mechanism or develop viable DNA vaccines,
our ability to support our broad pipeline of SynCon® active
immunotherapy and vaccine products, our ability to advance our
portfolio of immuno-oncology products independently, the ability of
our collaborators to attain development and commercial milestones
for products we license and product sales that will enable us to
receive future payments and royalties, the adequacy of our capital
resources, the availability or potential availability of
alternative therapies or treatments for the conditions targeted by
the company or its collaborators, including alternatives that may
be more efficacious or cost effective than any therapy or treatment
that the company and its collaborators hope to develop, our ability
to enter into partnerships in conjunction with our research and
development programs, evaluation of potential opportunities, issues
involving product liability, issues involving patents and whether
they or licenses to them will provide the company with meaningful
protection from others using the covered technologies, whether such
proprietary rights are enforceable or defensible or infringe or
allegedly infringe on rights of others or can withstand claims of
invalidity and whether the company can finance or devote other
significant resources that may be necessary to prosecute, protect
or defend them, the level of corporate expenditures, assessments of
the company's technology by potential corporate or other partners
or collaborators, capital market conditions, the impact of
government healthcare proposals and other factors set forth in our
Annual Report on Form 10-K for the year ended December 31, 2015,
our Form 10-Q for the quarter ended March 31, 2016, and
other regulatory filings from time to time. There can be no
assurance that any product in Inovio's pipeline will be
successfully developed or manufactured, that final results of
clinical studies will be supportive of regulatory approvals
required to market licensed products, or that any of the
forward-looking information provided herein will be proven
accurate.
CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Sep 2023 to Sep 2024